ClinicalTrials.gg
CompletedNCT02453256focuSScedUpdated Mar 9, 2020Results posted

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

A Phase 3 interventional study of Placebo and Tocilizumab in Systemic Sclerosis, sponsored by Hoffmann-La Roche. Completed at 83 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
19th of 142
212 · median 34
Started
2015
with 6 others
Phase 3
12 of 165
3 open now
Registered
69th of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 19th largest by enrollment of the 142 interventional ones that give a count, is one of 7 that started in 2015, is one of 12 in phase 3, and was the 69th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. In the open-label period, eligible participants from either arm may receive active tocilizumab.

03

Conditions studied

  • Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SSc according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria, meeting criteria for active disease and with total disease duration of less than or equal to (\</=) 60 months
  • mRSS of 10-35 units, inclusive
  • Agreement to remain abstinent or use an effective method among males and females with

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Major surgery within 8 weeks prior to screening
  • Scleroderma limited to the face or areas distal to the elbows or knees
  • Rheumatic disease other than SSc
  • Immunization with a live or attenuated vaccine within 4 weeks prior to Baseline
  • Known to human, humanized, or murine monoclonal antibodies
  • Moderately severe nervous system, renal, endocrine, pulmonary, cardiovascular, or gastrointestinal (GI) disease not related to SSc, including diverticulitis or ulcerative lower GI disorders, or myocardial infarction (MI) within 6 months prior to screening
  • Active or significant history of infection, including treatment with intravenous (IV) antibiotics within 4 weeks or oral antibiotics within 2 weeks prior to screening
  • Significant history of tuberculosis (TB)
  • Primary or secondary immunodeficiency
  • Malignant disease, with the exception of excised/cured local basal or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix
  • History of drug or alcohol abuse
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
212 participants (actual)

Study arms

  • Placebo comparator
    Double-Blind Placebo

    Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.

    Drug: Placebo · Drug: Tocilizumab

  • Experimental
    Double-Blind Tocilizumab

    Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.

    Drug: Tocilizumab

Interventions

  • DrugPlacebo

    Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.

  • Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.

06

What researchers measure

Primary outcomes

  1. Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period

    The efficacy of TCZ vs placebo is evaluated in terms of in mean change in mRSS. Skin thickness will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.

    Time frame: From baseline to week 48

Secondary outcomes

  1. Percentage of Participants With Greater Than or Equal to (>/=) 20%, 40%, or 60% Improvement in mRSS During Double-blind Period

    The proportion of participants with threshold improvements in mRSS at Week 48 relative to baseline.

    Time frame: From Baseline to Week 48

  2. Change From Baseline in Percent Predicted FVC (ppFVC) During Double-blind Period

    FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.

    Time frame: Baseline to week 48

  3. Change in Forced Vital Capacity (FVC) During Double-blind Period

    FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.

    Time frame: From Baseline to Week 48

  4. Change in Health Assessment Questionnaire Disability Index (HAQ-DI) Score During Double-blind Period

    The Health Assessment Questionnaire Disability Index (HAQ-DI) consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The total score indicates the patient's self-assessed level of disability. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.

    Time frame: From Baseline to Week 48

  5. Change in Patient Global Assessment Score During Double-blind Period

    The Patient's Global Assessment represents the patient's overall assessment of current SSc status on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."

    Time frame: From Baseline to Week 48

  6. Change in Physician Global Assessment Score During Double-blind Period

    The Physician's Global Assessment is to be completed on the basis of examination and overall assessment of the patient. The physician's assessment of the patient's SSc status will be scored on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."

    Time frame: From Baseline to Week 48

  7. Time to Treatment Failure According to mRSS, FVC, or Protocol-Specified Event During Double-blind Period

    Time to treatment failure is defined as the time from randomization to the time of death, decline in percent-predicted FVC \> 10% relative to baseline, \> 20% increase in mRSS and an increase in mRSS of equal to or more than 5 points, or occurrence of a predefined SSc-related complication as adjudicated by the Clinical Adjudication Committee (whichever occurs first) during the 48-week double-blind treatment period. The median TTF was not estimable and is not presented for either treatment arm because of the low number of patients with events at Week 48.

    Time frame: From Baseline to Week 48

  8. Summary of Adverse Events During Double-blind Period

    Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 20.1. NMSC = Non-Melanoma Skin Cancer

    Time frame: From Baseline until Week 48

  9. Incidence and Severity of Adverse Events During Double-blind Period

    Adverse events listed according to MedDRA version 20.1 preferred terms and severity grade.

    Time frame: From Baseline until Week 48

  10. Number of Participants With Adverse Events Leading to Death During Double-blind Period

    Reason of death is coded using MedDRA 20.1

    Time frame: From Baseline up to Week 48

  11. Frequency of Serious Systemic Sclerosis (SSC) Related Complications During Double-blind Period

    Adverse event terms coded using MedDRA 20.1. Includes only those serious events adjudicated as SSC-related complications by an independent external committee.

    Time frame: From Baseline up to Week 48

  12. Incidence of Haematology and Hepatic Laboratory Parameters During Double-blind Period

    A laboratory event occurred if the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade for a post-baseline laboratory measurement increased from baseline.

    Time frame: From Baseline up to Week 48

  13. Percentage of Participants With Change in Digital Ulcer Count During Double-blind Period

    A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.

    Time frame: From Baseline to Week 48

  14. Percentage of Participants With Positive Anti-Tocilizumab Assay Result at Baseline

    Incidence of anti-Tocilizumab at baseline

    Time frame: Baseline

  15. Percentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline up to Week 48

    Incidence of anti-Tocilizumab antibodies during the study relative to the prevalence of anti-Tocilizumab antibodies at baseline. Samples that are positive for anti-TCZ in the screening assay will be further analyzed by a confirmation assay to confirm specificity. If the confirmation assay is positive, two additional tests will be performed: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.

    Time frame: Double-blind period (up to Week 48)

  16. Correlation Between Anti-Tocilizumab Antibody Status and Outcome Measures Pertaining to the Efficacy, Safety, and Pharmacokinetics of Tocilizumab

    Pre-specified analysis of the relationship between Anti-Tocilizumab Antibody status and safety, efficacy, and PK endpoints were not analyzed via subgroup analyses as there was only 1 patient with ADA-positive status.

    Time frame: Baseline; during Weeks 8, 16, 24, 36, 48, 96, and/or at treatment discontinuation (up to 96 weeks); and 8 weeks after treatment discontinuation (up to 104 weeks overall)

  17. Erythrocyte Sedimentation Rate (ESR), Mean, From Baseline to Week 48

    Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Predose up to Week 48

  18. Erythrocyte Sedimentation Rate (ESR), Median, From Baseline to Week 48

    Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  19. Serum Interleukin (IL)-6 Level, Mean, From Baseline to Week 48

    Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  20. Serum Interleukin (IL)-6 Level, Median, From Baseline to Week 48

    Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  21. Serum Interleukin (IL)-6 Level, Mean Change From Baseline to Week 48

    Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  22. Serum Interleukin (IL)-6 Level, Median Change From Baseline to Week 48

    Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  23. Serum Soluble Interleukin (IL)-6 Receptor Level, Mean, From Baseline to Week 48

    Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  24. Serum Soluble Interleukin (IL)-6 Receptor Level, Median, From Baseline to Week 48

    Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  25. Serum Soluble Interleukin (IL)-6 Receptor Level, Mean Change From Baseline to Week 48

    Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  26. Serum Soluble Interleukin (IL)-6 Receptor Level, Median Change From Baseline to Week 48

    Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline to Week 48

  27. Serum C-Reactive Protein (CRP) Level, Mean, From Baseline to Week 48

    Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline up to Week 48

  28. Serum C-Reactive Protein (CRP) Level, Median, From Baseline to Week 48

    Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline up to Week 48

  29. Serum Tocilizumab Concentration, Mean, From Baseline to Week 48

    Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter

    Time frame: From Baseline to Week 48

  30. Serum Tocilizumab Concentration, Median, From Baseline to Week 48

    Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter

    Time frame: From Baseline to Week 48

  31. Correlation Between Low Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  32. Correlation Between Low Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  33. Correlation Between Medium Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  34. Correlation Between Medium Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  35. Correlation Between High Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  36. Correlation Between High Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  37. Change in Mean Modified Rodnan Skin Score (mRSS) at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  38. Change in Median Modified Rodnan Skin Score (mRSS), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  39. Change in Mean Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  40. Change in Median Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

    In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

    Time frame: From Baseline to Week 48

  41. Summary of Adverse Events Up to Week 96

    Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 21.1. NMSC = Non-Melanoma Skin Cancer

    Time frame: Up to Week 96

  42. Incidence and Severity of Adverse Events Up to Week 96

    Adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) severity grade: 1 = mild, 2 = moderate, 3 = severe and/or requiring medical intervention but not life-threatening, 4 = life-threatening consequences, and 5 = death.

    Time frame: Up to Week 96

  43. Number of Participants With Adverse Events Leading to Death Up to Week 96

    Time frame: Up to Week 96

  44. Percentage of Participants With Change in Digital Ulcer Count at Week 96

    A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.

    Time frame: From Baseline to Week 96

  45. Percentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline From Week 48 to 96

    Reported were the percentage of participants with post-baseline treatment-induced anti-TCZ antibodies. Positive samples underwent additional analyses: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.

    Time frame: Open-label period from Week 48 to 96

  46. Erythrocyte Sedimentation Rate (ESR) Up to Week 96

    Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: Up to Week 96

  47. Serum Interleukin (IL)-6 Level, Mean, From Baseline to Week 96

    Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: Up to Week 96

  48. Serum Soluble Interleukin (IL)-6 Receptor Level, Mean, Up to Week 96

    Serum Soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: Up to Week 96

  49. Serum C-Reactive Protein (CRP) Level, Mean, Up to Week 96

    Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.

    Time frame: From Baseline up to Week 96

  50. Serum Tocilizumab Concentration, Mean, Up to Week 96

    Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter

    Time frame: Up to Week 96

07

Results

Posted Apr 3, 2019

Participant flow

Double Blind Period
Participant flow — Double Blind Period
MilestoneDouble-Blind Placebo, Then Open Label TocilizumabDouble-Blind Tocilizumab, Then Open Label Tocilizumab
Started106104
Completed9395
Not completed139
Withdrew: Death11
Withdrew: Adverse event32
Withdrew: Withdrawal by subject95
Withdrew: Other01
Open Label Period
Participant flow — Open Label Period
MilestoneDouble-Blind Placebo, Then Open Label TocilizumabDouble-Blind Tocilizumab, Then Open Label Tocilizumab
Started8992
Completed8285
Not completed77
Withdrew: Adverse event13
Withdrew: Death01
Withdrew: Lost to follow-up10
Withdrew: Other02
Withdrew: Withdrawal by subject51

Outcome measures

PrimaryChange in Modified Rodnan Skin Score (mRSS) During Double-blind Period

The efficacy of TCZ vs placebo is evaluated in terms of in mean change in mRSS. Skin thickness will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.

Time frame:
From baseline to week 48
Reported as:
Least squares mean · Units on a scale
Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period-4.41 (-5.96 to -2.86)-6.14 (-7.71 to -4.57)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Repeated Measure · p = 0.0983 · Difference in least square means: -1.73 · 95% CI -3.78 to 0.32
SecondaryPercentage of Participants With Greater Than or Equal to (>/=) 20%, 40%, or 60% Improvement in mRSS During Double-blind Period

The proportion of participants with threshold improvements in mRSS at Week 48 relative to baseline.

Time frame:
From Baseline to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Greater Than or Equal to (>/=) 20%, 40%, or 60% Improvement in mRSS During Double-blind Period
Percentage of ParticipantsDouble-Blind PlaceboDouble-Blind Tocilizumab
≥ 20%50.0 (40.01 to 59.99)72.1 (63.02 to 81.21)
≥ 40%37.7 (28.04 to 47.44)42.3 (32.33 to 52.28)
≥ 60%22.6 (14.20 to 31.08)17.3 (9.56 to 25.06)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Cochran-Mantel-Haenszel · p = 0.0007 · Weighted difference: 21.91 · 95% CI 9.2 to 34.6
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Cochran-Mantel-Haenszel · p = 0.5139 · Weighted difference: 4.32 · 95% CI -8.7 to 17.3
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Cochran-Mantel-Haenszel · p = 0.3276 · Weighted difference: -5.41 · 95% CI -16.2 to 5.4
SecondaryChange From Baseline in Percent Predicted FVC (ppFVC) During Double-blind Period

FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.

Time frame:
Baseline to week 48
Reported as:
Median · Percent Predicted FVC
Change From Baseline in Percent Predicted FVC (ppFVC) During Double-blind Period
Percent Predicted FVCDouble-Blind PlaceboDouble-Blind Tocilizumab
Change From Baseline in Percent Predicted FVC (ppFVC) During Double-blind Period-3.910 (-4.820 to -1.620)-0.600 (-2.380 to 0.880)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Van Elteren · p = 0.0015 (P-value from Van Elteren analysis stratified by IL-6 level (\<10; \>=10 pg/mL) at screening.)
SecondaryChange in Forced Vital Capacity (FVC) During Double-blind Period

FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.

Time frame:
From Baseline to Week 48
Reported as:
Least squares mean · Liters of air
Change in Forced Vital Capacity (FVC) During Double-blind Period
Liters of airDouble-Blind PlaceboDouble-Blind Tocilizumab
Change in Forced Vital Capacity (FVC) During Double-blind Period-0.19 (-0.25 to -0.13)-0.02 (-0.09 to 0.04)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Repeated Measure · p = 0.0001 · Difference in least square means: 0.167 · 95% CI 0.083 to 0.250
SecondaryChange in Health Assessment Questionnaire Disability Index (HAQ-DI) Score During Double-blind Period

The Health Assessment Questionnaire Disability Index (HAQ-DI) consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The total score indicates the patient's self-assessed level of disability. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.

Time frame:
From Baseline to Week 48
Reported as:
Least squares mean · Scores on a Scale
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) Score During Double-blind Period
Scores on a ScaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) Score During Double-blind Period-0.06 (-0.16 to 0.05)-0.11 (-0.22 to -0.01)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Repeated Measure · p = 0.4489 · Difference in least square means: -0.053 · 95% CI -0.192 to 0.085
SecondaryChange in Patient Global Assessment Score During Double-blind Period

The Patient's Global Assessment represents the patient's overall assessment of current SSc status on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."

Time frame:
From Baseline to Week 48
Reported as:
Least squares mean · mm
Change in Patient Global Assessment Score During Double-blind Period
mmDouble-Blind PlaceboDouble-Blind Tocilizumab
Change in Patient Global Assessment Score During Double-blind Period-7.66 (-12.31 to -3.02)-10.10 (-14.79 to -5.41)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Repeated Measure · p = 0.4339 · Difference in least square means: -2.44 · 95% CI -8.57 to 3.70
SecondaryChange in Physician Global Assessment Score During Double-blind Period

The Physician's Global Assessment is to be completed on the basis of examination and overall assessment of the patient. The physician's assessment of the patient's SSc status will be scored on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."

Time frame:
From Baseline to Week 48
Reported as:
Least squares mean · mm
Change in Physician Global Assessment Score During Double-blind Period
mmDouble-Blind PlaceboDouble-Blind Tocilizumab
Change in Physician Global Assessment Score During Double-blind Period-19.99 (-24.76 to -15.22)-22.45 (-27.33 to -17.57)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Repeated Measure · p = 0.4378 · Difference in least square means: -2.46 · 95% CI -8.72 to 3.79
SecondaryTime to Treatment Failure According to mRSS, FVC, or Protocol-Specified Event During Double-blind Period

Time to treatment failure is defined as the time from randomization to the time of death, decline in percent-predicted FVC \> 10% relative to baseline, \> 20% increase in mRSS and an increase in mRSS of equal to or more than 5 points, or occurrence of a predefined SSc-related complication as adjudicated by the Clinical Adjudication Committee (whichever occurs first) during the 48-week double-blind treatment period. The median TTF was not estimable and is not presented for either treatment arm because of the low number of patients with events at Week 48.

Time frame:
From Baseline to Week 48
Reported as:
Median · months
Time to Treatment Failure According to mRSS, FVC, or Protocol-Specified Event During Double-blind Period
monthsDouble-Blind PlaceboDouble-Blind Tocilizumab
Time to Treatment Failure According to mRSS, FVC, or Protocol-Specified Event During Double-blind PeriodNA (48.7 to NA)NA (NA to NA)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Tocilizumab · Cox-proportional hazards model · p = 0.0821 · Hazard ratio (hr): 0.63 · 95% CI 0.37 to 1.06
SecondarySummary of Adverse Events During Double-blind Period

Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 20.1. NMSC = Non-Melanoma Skin Cancer

Time frame:
From Baseline until Week 48
Reported as:
Number · Percentage of Participants
Summary of Adverse Events During Double-blind Period
Percentage of ParticipantsDouble-Blind PlaceboDouble-Blind Tocilizumab
At least one Adverse Event (AE)77.485.6
Withdrawn from study due to an AE3.82.9
Fatal AE2.81.0
Serious Adverse Events (SAEs)17.012.5
SAE leading to withdrawal from treatment3.83.8
SAE leading to dose modification/interruption6.62.9
SAE related to study drug6.61.0
AE leading to withdrawal from treatment10.45.8
AE leading to dose modification/interruption25.519.2
AE related to study drug34.946.2
Related AE leading to withdrawal from treatment1.91.0
Related AE with dose modification/interruption16.011.5
Infections and Infestations SAE6.61.9
Infections and Infestations AE50.051.9
Opportunistic Infections and Infestations AE0.90.0
Malignancy AE0.91.9
Malignancy AE (excluding NMSC)0.91.9
At least one Hepatic SAE0.00.0
At least one Stroke SAE0.00.0
At least one Myocardial Infarction SAE1.90.0
At least one Anaphylactic Reaction AE0.00.0
Anaphylactic Reaction AE (Sampson's Criteria)0.00.0
At least one Gastrointestinal Perforation SAE0.00.0
At least one Bleeding SAE0.90.0
At least one Demyelinating SAE0.00.0
SecondaryIncidence and Severity of Adverse Events During Double-blind Period

Adverse events listed according to MedDRA version 20.1 preferred terms and severity grade.

Time frame:
From Baseline until Week 48
Reported as:
Number · Number of participants
Incidence and Severity of Adverse Events During Double-blind Period
Number of participantsDouble-Blind PlaceboDouble-Blind Tocilizumab
NASOPHARYNGITIS GRADE 1610
NASOPHARYNGITIS GRADE 223
URINARY TRACT INFECTION GRADE 151
URINARY TRACT INFECTION GRADE 253
URINARY TRACT INFECTION GRADE 301
GASTROENTERITIS GRADE 102
GASTROENTERITIS GRADE 224
HERPES ZOSTER GRADE 250
HERPES ZOSTER GRADE 302
PHARYNGITIS GRADE 121
PHARYNGITIS GRADE 222
INFECTED SKIN ULCER GRADE 101
INFECTED SKIN ULCER GRADE 213
INFECTED SKIN ULCER GRADE 310
BRONCHITIS GRADE 111
BRONCHITIS GRADE 212
INFLUENZA GRADE 112
INFLUENZA GRADE 211
LATENT TUBERCULOSIS GRADE 112
LATENT TUBERCULOSIS GRADE 202
PNEUMONIA GRADE 211
PNEUMONIA GRADE 330
RESPIRATORY TRACT INFECTION GRADE 111
RESPIRATORY TRACT INFECTION GRADE 201
RESPIRATORY TRACT INFECTION GRADE 310
SINUSITIS GRADE 110
SINUSITIS GRADE 211
SINUSITIS GRADE 301
WOUND INFECTION GRADE 102
WOUND INFECTION GRADE 210
WOUND INFECTION GRADE 310
CYSTITIS GRADE 101
CYSTITIS GRADE 202
LOCALISED INFECTION GRADE 110
LOCALISED INFECTION GRADE 220
ORAL CANDIDIASIS GRADE 121
PARONYCHIA GRADE 220
PARONYCHIA GRADE 310
VULVOVAGINAL MYCOTIC INFECTION GRADE 221
CANDIDA INFECTION GRADE 110
CANDIDA INFECTION GRADE 210
FOLLICULITIS GRADE 101
FOLLICULITIS GRADE 210
GASTROINTESTINAL INFECTION GRADE 220
HORDEOLUM GRADE 102
RHINITIS GRADE 211
SOFT TISSUE INFECTION GRADE 210
SOFT TISSUE INFECTION GRADE 410
TINEA PEDIS GRADE 101
TINEA PEDIS GRADE 201
VIRAL UPPER RESPIRATORY TRACT INFECTION GRADE 110
VIRAL UPPER RESPIRATORY TRACT INFECTION GRADE 210
ABSCESS JAW GRADE 310
ACUTE SINUSITIS GRADE 210
BACTERAEMIA GRADE 210
BODY TINEA GRADE 110
CAMPYLOBACTER GASTROENTERITIS GRADE 101
GASTROENTERITIS VIRAL GRADE 210
GASTROINTESTINAL BACTERIAL OVERGROWTH GRADE 210
GASTROINTESTINAL VIRAL INFECTION GRADE 110
GINGIVITIS GRADE 210
HERPES SIMPLEX GRADE 110
INFECTIOUS MONONUCLEOSIS GRADE 110
LARYNGITIS GRADE 110
LICE INFESTATION GRADE 301
OESOPHAGEAL CANDIDIASIS GRADE 210
ORAL HERPES GRADE 210
OSTEOMYELITIS GRADE 301
PELVIC INFLAMMATORY DISEASE GRADE 301
PERIODONTITIS GRADE 210
PERIORBITAL CELLULITIS GRADE 101
PHARYNGITIS STREPTOCOCCAL GRADE 110
PULMONARY TUBERCULOSIS GRADE 301
PULPITIS DENTAL GRADE 101
PYELONEPHRITIS CHRONIC GRADE 310
RASH PUSTULAR GRADE 101
RESPIRATORY TRACT INFECTION BACTERIAL GRADE 201
SEPSIS GRADE 310
SKIN BACTERIAL INFECTION GRADE 210
TONSILLITIS GRADE 201
TOOTH INFECTION GRADE 310
VIRAL INFECTION GRADE 101
WOUND INFECTION STAPHYLOCOCCAL GRADE 101
ARTHRALGIA GRADE 138
ARTHRALGIA GRADE 283
ARTHRALGIA GRADE 310
BACK PAIN GRADE 111
BACK PAIN GRADE 241
MUSCLE SPASMS GRADE 112
MUSCLE SPASMS GRADE 211
MUSCLE SPASMS GRADE 310
PAIN IN EXTREMITY GRADE 122
PAIN IN EXTREMITY GRADE 201
PAIN IN EXTREMITY GRADE 310
MUSCULOSKELETAL PAIN GRADE 110
MUSCULOSKELETAL PAIN GRADE 240
BURSITIS GRADE 130
BURSITIS GRADE 201
MYALGIA GRADE 110
MYALGIA GRADE 230
ARTHRITIS GRADE 221
INTERVERTEBRAL DISC PROTRUSION GRADE 111
INTERVERTEBRAL DISC PROTRUSION GRADE 201
MYOSITIS GRADE 110
MYOSITIS GRADE 211
OSTEOCHONDROSIS GRADE 112
FOOT DEFORMITY GRADE 111
SCLERODERMA GRADE 201
SCLERODERMA GRADE 410
SJOGREN'S SYNDROME GRADE 110
SJOGREN'S SYNDROME GRADE 210
SPINAL OSTEOARTHRITIS GRADE 101
SPINAL OSTEOARTHRITIS GRADE 210
EXTREMITY CONTRACTURE GRADE 110
FIBROMYALGIA GRADE 110
FLANK PAIN GRADE 101
JOINT STIFFNESS GRADE 101
JOINT SWELLING GRADE 210
MUSCLE CONTRACTURE GRADE 101
MUSCLE FATIGUE GRADE 110
MUSCULAR WEAKNESS GRADE 201
MUSCULOSKELETAL CHEST PAIN GRADE 110
MYOPATHY GRADE 110
NECK PAIN GRADE 210
OSTEOPENIA GRADE 101
OSTEOPOROSIS GRADE 201
OSTEOPOROTIC FRACTURE GRADE 210
PAIN IN JAW GRADE 110
POLYARTHRITIS GRADE 210
TENOSYNOVITIS GRADE 201
TENOSYNOVITIS STENOSANS GRADE 110
SKIN ULCER GRADE 158
SKIN ULCER GRADE 275
SKIN ULCER GRADE 302
PRURITUS GRADE 121
PRURITUS GRADE 225
RASH GRADE 142
RASH GRADE 230
ERYTHEMA GRADE 114
ECZEMA GRADE 102
ECZEMA GRADE 220
ROSACEA GRADE 101
ROSACEA GRADE 211
SKIN TIGHTNESS GRADE 121
DERMATITIS CONTACT GRADE 211
INGROWING NAIL GRADE 101
INGROWING NAIL GRADE 210
MACULE GRADE 111
NIGHT SWEATS GRADE 120
SKIN DISCOLOURATION GRADE 102
SKIN FISSURES GRADE 102
SKIN HYPERTROPHY GRADE 102
SKIN INDURATION GRADE 120
URTICARIA GRADE 101
URTICARIA GRADE 210
ALOPECIA GRADE 101
BLISTER GRADE 201
CHLOASMA GRADE 110
COLD SWEAT GRADE 110
DECUBITUS ULCER GRADE 201
DERMATITIS ACNEIFORM GRADE 101
DERMATITIS ATOPIC GRADE 101
DIGITAL PITTING SCAR GRADE 410
DRY SKIN GRADE 101
ECCHYMOSIS GRADE 310
EXCESSIVE GRANULATION TISSUE GRADE 301
HYPERTRICHOSIS GRADE 110
ONYCHOLYSIS GRADE 110
PAIN OF SKIN GRADE 110
PAPULE GRADE 110
RASH ERYTHEMATOUS GRADE 101
RASH MACULO-PAPULAR GRADE 301
SKIN DEPIGMENTATION GRADE 110
SKIN FIBROSIS GRADE 210
SKIN HYPOPIGMENTATION GRADE 110
SKIN OEDEMA GRADE 110
VITILIGO GRADE 210
DIARRHOEA GRADE 156
DIARRHOEA GRADE 230
GASTROOESOPHAGEAL REFLUX DISEASE GRADE 133
GASTROOESOPHAGEAL REFLUX DISEASE GRADE 221
NAUSEA GRADE 153
NAUSEA GRADE 210
ABDOMINAL PAIN GRADE 131
ABDOMINAL PAIN GRADE 210
ABDOMINAL PAIN GRADE 310
CONSTIPATION GRADE 122
CONSTIPATION GRADE 220
DYSPEPSIA GRADE 112
DYSPEPSIA GRADE 211
DYSPHAGIA GRADE 122
DYSPHAGIA GRADE 201
STOMATITIS GRADE 111
STOMATITIS GRADE 210
VOMITING GRADE 111
VOMITING GRADE 301
ABDOMINAL DISCOMFORT GRADE 101
ABDOMINAL DISCOMFORT GRADE 210
ABDOMINAL DISTENSION GRADE 110
ABDOMINAL DISTENSION GRADE 210
ABDOMINAL PAIN UPPER GRADE 111
DENTAL CARIES GRADE 211
FAECES SOFT GRADE 111
HAEMORRHOIDS GRADE 110
HAEMORRHOIDS GRADE 210
TOOTHACHE GRADE 220
ANAL HAEMORRHAGE GRADE 210
CHRONIC GASTRITIS GRADE 110
DIVERTICULUM INTESTINAL GRADE 101
DRY MOUTH GRADE 201
DUODENITIS GRADE 101
GASTRIC DISORDER GRADE 101
GASTRIC POLYPS GRADE 110
GASTRITIS GRADE 210
HAEMATOCHEZIA GRADE 101
ILEUS PARALYTIC GRADE 310
LOOSE TOOTH GRADE 101
OESOPHAGEAL DISORDER GRADE 110
OESOPHAGEAL HYPOMOTILITY GRADE 201
PERIODONTAL DISEASE GRADE 210
PNEUMATOSIS INTESTINALIS GRADE 201
RANULA GRADE 101
SWOLLEN TONGUE GRADE 201
FATIGUE GRADE 137
FATIGUE GRADE 241
OEDEMA PERIPHERAL GRADE 121
OEDEMA PERIPHERAL GRADE 210
ASTHENIA GRADE 120
ASTHENIA GRADE 310
CALCINOSIS GRADE 112
INJECTION SITE ERYTHEMA GRADE 101
INJECTION SITE ERYTHEMA GRADE 201
INJECTION SITE ERYTHEMA GRADE 301
INJECTION SITE REACTION GRADE 101
INJECTION SITE REACTION GRADE 211
PAIN GRADE 210
PAIN GRADE 301
PAIN GRADE 410
CHEST PAIN GRADE 120
CYST GRADE 110
CYST GRADE 210
INFLUENZA LIKE ILLNESS GRADE 111
DEATH GRADE 501
FEELING HOT GRADE 101
GRANULOMA GRADE 110
INJECTION SITE EXTRAVASATION GRADE 101
INJECTION SITE INDURATION GRADE 201
INJECTION SITE PRURITUS GRADE 201
MALAISE GRADE 101
NODULE GRADE 110
PERIPHERAL SWELLING GRADE 210
PYREXIA GRADE 110
SENSATION OF FOREIGN BODY GRADE 101
VESSEL PUNCTURE SITE PAIN GRADE 101
WEIGHT DECREASED GRADE 131
WEIGHT DECREASED GRADE 232
ALANINE AMINOTRANSFERASE INCREASED GRADE 102
ALANINE AMINOTRANSFERASE INCREASED GRADE 220
ALANINE AMINOTRANSFERASE INCREASED GRADE 302
ASPARTATE AMINOTRANSFERASE INCREASED GRADE 102
ASPARTATE AMINOTRANSFERASE INCREASED GRADE 220
ASPARTATE AMINOTRANSFERASE INCREASED GRADE 301
HEPATIC ENZYME INCREASED GRADE 110
HEPATIC ENZYME INCREASED GRADE 211
HEPATIC ENZYME INCREASED GRADE 310
WEIGHT INCREASED GRADE 122
TRANSAMINASES INCREASED GRADE 101
TRANSAMINASES INCREASED GRADE 220
BLOOD CHOLESTEROL INCREASED GRADE 101
BLOOD CHOLESTEROL INCREASED GRADE 201
UPPER RESPIRATORY TRACT INFECTION GRADE 147
UPPER RESPIRATORY TRACT INFECTION GRADE 274
UPPER RESPIRATORY TRACT INFECTION GRADE 301
BLOOD CREATINE PHOSPHOKINASE INCREASED GRADE 101
BLOOD CREATINE PHOSPHOKINASE INCREASED GRADE 201
BLOOD BILIRUBIN INCREASED GRADE 101
BLOOD URINE PRESENT GRADE 210
CAROTID INTIMA-MEDIA THICKNESS INCREASED GRADE 110
COMPUTERISED TOMOGRAM THORAX ABNORMAL GRADE 210
HAEMOGLOBIN DECREASED GRADE 210
LIVER FUNCTION TEST ABNORMAL GRADE 201
LOW DENSITY LIPOPROTEIN INCREASED GRADE 201
PROTEIN URINE PRESENT GRADE 210
TRANSFERRIN SATURATION INCREASED GRADE 101
TUBERCULIN TEST POSITIVE GRADE 210
URINE BILIRUBIN INCREASED GRADE 210
UROBILINOGEN URINE INCREASED GRADE 210
WHITE BLOOD CELLS URINE POSITIVE GRADE 110
COUGH GRADE 131
COUGH GRADE 222
INTERSTITIAL LUNG DISEASE GRADE 130
INTERSTITIAL LUNG DISEASE GRADE 250
DYSPNOEA GRADE 111
DYSPNOEA GRADE 222
EPISTAXIS GRADE 131
EPISTAXIS GRADE 201
DYSPNOEA EXERTIONAL GRADE 110
DYSPNOEA EXERTIONAL GRADE 210
DYSPNOEA EXERTIONAL GRADE 310
OROPHARYNGEAL PAIN GRADE 111
OROPHARYNGEAL PAIN GRADE 210
PRODUCTIVE COUGH GRADE 120
DYSPHONIA GRADE 110
HAEMOPTYSIS GRADE 101
PAINFUL RESPIRATION GRADE 110
PLEURAL EFFUSION GRADE 410
PNEUMONITIS GRADE 210
RHINITIS ALLERGIC GRADE 110
RHINORRHOEA GRADE 110
HEADACHE GRADE 133
HEADACHE GRADE 240
DIZZINESS GRADE 122
DIZZINESS GRADE 211
NEUROPATHY PERIPHERAL GRADE 220
POST HERPETIC NEURALGIA GRADE 220
CARPAL TUNNEL SYNDROME GRADE 110
DYSGEUSIA GRADE 110
HYPOAESTHESIA GRADE 110
HYPOKINESIA GRADE 301
MEMORY IMPAIRMENT GRADE 101
NERVE COMPRESSION GRADE 110
NEURALGIA GRADE 110
PARAESTHESIA GRADE 101
PARKINSONISM GRADE 210
PRESYNCOPE GRADE 101
RADICULAR PAIN GRADE 101
SENSORY LOSS GRADE 110
SOMNOLENCE GRADE 101
LIMB INJURY GRADE 121
LIMB INJURY GRADE 220
LIMB INJURY GRADE 301
FALL GRADE 101
FALL GRADE 202
EAR INJURY GRADE 102
LACERATION GRADE 110
LACERATION GRADE 210
SCAR GRADE 101
SCAR GRADE 210
WOUND GRADE 101
WOUND GRADE 210
ANIMAL BITE GRADE 201
ANKLE FRACTURE GRADE 101
ARTHROPOD STING GRADE 110
CONTUSION GRADE 101
CRANIOCEREBRAL INJURY GRADE 210
EXCORIATION GRADE 101
FACE INJURY GRADE 101
INJURY CORNEAL GRADE 210
JOINT INJURY GRADE 301
LIGAMENT SPRAIN GRADE 101
LIMB TRAUMATIC AMPUTATION GRADE 301
MENISCUS INJURY GRADE 301
MUSCLE RUPTURE GRADE 201
MUSCLE STRAIN GRADE 210
ROAD TRAFFIC ACCIDENT GRADE 101
SKIN ABRASION GRADE 110
SPINAL COMPRESSION FRACTURE GRADE 210
THERMAL BURN GRADE 101
ANAEMIA GRADE 130
ANAEMIA GRADE 221
ANAEMIA GRADE 310
IRON DEFICIENCY ANAEMIA GRADE 110
IRON DEFICIENCY ANAEMIA GRADE 210
IRON DEFICIENCY ANAEMIA GRADE 301
LYMPHOPENIA GRADE 201
LYMPHOPENIA GRADE 310
NEUTROPENIA GRADE 201
NEUTROPENIA GRADE 310
ANAEMIA MEGALOBLASTIC GRADE 210
EOSINOPHILIA GRADE 101
LEUKOCYTOSIS GRADE 110
LEUKOPENIA GRADE 201
LYMPHADENOPATHY MEDIASTINAL GRADE 210
MICROANGIOPATHIC HAEMOLYTIC ANAEMIA GRADE 201
MICROCYTIC ANAEMIA GRADE 101
THROMBOCYTOPENIA GRADE 101
DECREASED APPETITE GRADE 141
DYSLIPIDAEMIA GRADE 102
DYSLIPIDAEMIA GRADE 211
HYPERCHOLESTEROLAEMIA GRADE 101
HYPERCHOLESTEROLAEMIA GRADE 201
HYPERTRIGLYCERIDAEMIA GRADE 211
DIABETES MELLITUS GRADE 210
DIABETIC KETOACIDOSIS GRADE 410
DIABETIC METABOLIC DECOMPENSATION GRADE 101
FOLATE DEFICIENCY GRADE 101
GOUT GRADE 210
HYPERGLYCAEMIA GRADE 310
HYPERLIPIDAEMIA GRADE 101
HYPONATRAEMIA GRADE 110
IRON DEFICIENCY GRADE 210
OBESITY GRADE 101
WEIGHT FLUCTUATION GRADE 110
PALPITATIONS GRADE 141
PALPITATIONS GRADE 301
BUNDLE BRANCH BLOCK RIGHT GRADE 110
BUNDLE BRANCH BLOCK RIGHT GRADE 201
PERICARDIAL EFFUSION GRADE 110
PERICARDIAL EFFUSION GRADE 210
ACUTE MYOCARDIAL INFARCTION GRADE 310
ANGINA PECTORIS GRADE 301
ATRIAL FIBRILLATION GRADE 310
ATRIAL TACHYCARDIA GRADE 210
BRADYCARDIA GRADE 101
CARDIAC FAILURE GRADE 301
CARDIAC FAILURE CHRONIC GRADE 510
MICROVASCULAR CORONARY ARTERY DISEASE GRADE 210
MYOCARDIAL INFARCTION GRADE 510
MYOCARDITIS GRADE 510
PERICARDITIS GRADE 210
SUPRAVENTRICULAR EXTRASYSTOLES GRADE 110
TACHYCARDIA GRADE 110
ANXIETY GRADE 121
ANXIETY GRADE 210
INSOMNIA GRADE 121
STRESS GRADE 111
ADJUSTMENT DISORDER GRADE 310
DEPRESSED MOOD GRADE 301
DEPRESSION GRADE 101
GENERALISED ANXIETY DISORDER GRADE 210
SLEEP DISORDER GRADE 110
CHALAZION GRADE 102
GLAUCOMA GRADE 101
GLAUCOMA GRADE 310
BLEPHARITIS GRADE 201
CATARACT GRADE 310
CONJUNCTIVAL HAEMORRHAGE GRADE 110
DRY EYE GRADE 101
EYELID OEDEMA GRADE 101
KERATITIS GRADE 201
VISUAL IMPAIRMENT GRADE 101
RAYNAUD'S PHENOMENON GRADE 113
RAYNAUD'S PHENOMENON GRADE 210
BLOOD PRESSURE FLUCTUATION GRADE 101
HYPERTENSION GRADE 201
HYPOTENSION GRADE 210
PERIPHERAL ISCHAEMIA GRADE 201
THROMBOPHLEBITIS GRADE 201
VASCULITIS GRADE 210
ACUTE KIDNEY INJURY GRADE 310
DYSURIA GRADE 110
HAEMATURIA GRADE 110
NEPHROLITHIASIS GRADE 301
RENAL COLIC GRADE 201
RENAL CYST GRADE 110
RENAL PAIN GRADE 210
SCLERODERMA RENAL CRISIS GRADE 301
AMENORRHOEA GRADE 101
BREAST CYST GRADE 110
CERVICAL POLYP GRADE 101
ERECTILE DYSFUNCTION GRADE 210
GENITAL RASH GRADE 210
MENSTRUATION IRREGULAR GRADE 110
OVARIAN CYST RUPTURED GRADE 210
PENILE PAIN GRADE 110
B-CELL LYMPHOMA GRADE 301
BENIGN BONE NEOPLASM GRADE 310
BENIGN LUNG NEOPLASM GRADE 101
BREAST CANCER GRADE 301
LUNG ADENOCARCINOMA GRADE 410
SKIN PAPILLOMA GRADE 201
FOOD ALLERGY GRADE 201
HYPERSENSITIVITY GRADE 101
TYPE I HYPERSENSITIVITY GRADE 201
MICROSTOMIA GRADE 110
MICROSTOMIA GRADE 201
PRESBYACUSIS GRADE 101
VERTIGO GRADE 110
HYPOTHYROIDISM GRADE 101
THYROID MASS GRADE 110
HEPATIC STEATOSIS GRADE 101
NEEDLE ISSUE GRADE 101
CATARACT OPERATION GRADE 310
SecondaryNumber of Participants With Adverse Events Leading to Death During Double-blind Period

Reason of death is coded using MedDRA 20.1

Time frame:
From Baseline up to Week 48
Reported as:
Number · Number of participants
Number of Participants With Adverse Events Leading to Death During Double-blind Period
Number of participantsDouble-Blind PlaceboDouble-Blind Tocilizumab
CARDIAC FAILURE CHRONIC10
MYOCARDITIS10
MYOCARDIAL INFARCTION10
DEATH01
SecondaryFrequency of Serious Systemic Sclerosis (SSC) Related Complications During Double-blind Period

Adverse event terms coded using MedDRA 20.1. Includes only those serious events adjudicated as SSC-related complications by an independent external committee.

Time frame:
From Baseline up to Week 48
Reported as:
Number · Number of Participants
Frequency of Serious Systemic Sclerosis (SSC) Related Complications During Double-blind Period
Number of ParticipantsDouble-Blind PlaceboDouble-Blind Tocilizumab
CARDIAC FAILURE01
CARDIAC FAILURE CHRONIC10
MICROVASCULAR CORONARY ARTERY DISEASE10
MYOCARDITIS10
INFECTED SKIN ULCER10
OSTEOMYELITIS01
WOUND INFECTION01
ILEUS PARALYTIC10
PAIN10
WEIGHT DECREASED01
SCLERODERMA10
HYPOKINESIA01
ADJUSTMENT DISORDER10
SCLERODERMA RENAL CRISIS01
DIGITAL PITTING SCAR10
SecondaryIncidence of Haematology and Hepatic Laboratory Parameters During Double-blind Period

A laboratory event occurred if the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade for a post-baseline laboratory measurement increased from baseline.

Time frame:
From Baseline up to Week 48
Reported as:
Number · Number of Participants
Incidence of Haematology and Hepatic Laboratory Parameters During Double-blind Period
Number of ParticipantsDouble-Blind PlaceboDouble-Blind Tocilizumab
High Alkaline Phosphatase71
High SGPT/ALT1732
High SGOT/AST1724
Low Neutrophils, Segmented, Abs227
Low Platelet09
High Bilirubin113
SecondaryPercentage of Participants With Change in Digital Ulcer Count During Double-blind Period

A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.

Time frame:
From Baseline to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Change in Digital Ulcer Count During Double-blind Period
Percentage of participantsDouble-Blind PlaceboDouble-Blind Tocilizumab
No change85.487.2
Increase by 13.45.3
Increase by 21.11.1
Increase by 300
Increase by 400
Increase by >41.10
Decrease by 13.44.3
Decrease by 23.40
Decrease by 301.1
Decrease by 41.10
Decrease by >400
Baseline missing1.11.1
SecondaryPercentage of Participants With Positive Anti-Tocilizumab Assay Result at Baseline

Incidence of anti-Tocilizumab at baseline

Time frame:
Baseline
Reported as:
Number · Percentage of Participants
Percentage of Participants With Positive Anti-Tocilizumab Assay Result at Baseline
Percentage of ParticipantsDouble-Blind PlaceboDouble-Blind Tocilizumab
Percentage of Participants With Positive Anti-Tocilizumab Assay Result at Baseline5.92.9
SecondaryPercentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline up to Week 48

Incidence of anti-Tocilizumab antibodies during the study relative to the prevalence of anti-Tocilizumab antibodies at baseline. Samples that are positive for anti-TCZ in the screening assay will be further analyzed by a confirmation assay to confirm specificity. If the confirmation assay is positive, two additional tests will be performed: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.

Time frame:
Double-blind period (up to Week 48)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline up to Week 48
Percentage of ParticipantsDouble-Blind PlaceboDouble-Blind Tocilizumab
Positive Anti-TCZ Assay0.02.9
Positive Confirmation Assay0.01.0
Positive Neutralizing Assay0.01.0
Positive IgE Assay0.00.0
SecondaryCorrelation Between Anti-Tocilizumab Antibody Status and Outcome Measures Pertaining to the Efficacy, Safety, and Pharmacokinetics of Tocilizumab

Pre-specified analysis of the relationship between Anti-Tocilizumab Antibody status and safety, efficacy, and PK endpoints were not analyzed via subgroup analyses as there was only 1 patient with ADA-positive status.

Time frame:
Baseline; during Weeks 8, 16, 24, 36, 48, 96, and/or at treatment discontinuation (up to 96 weeks); and 8 weeks after treatment discontinuation (up to 104 weeks overall)
Reported as:
Median · Units on a scale
Correlation Between Anti-Tocilizumab Antibody Status and Outcome Measures Pertaining to the Efficacy, Safety, and Pharmacokinetics of Tocilizumab
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Correlation Between Anti-Tocilizumab Antibody Status and Outcome Measures Pertaining to the Efficacy, Safety, and Pharmacokinetics of TocilizumabNA (NA to NA)NA (NA to NA)
SecondaryErythrocyte Sedimentation Rate (ESR), Mean, From Baseline to Week 48

Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Predose up to Week 48
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate (ESR), Mean, From Baseline to Week 48
mm/hrDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline34.72 ± 18.4934.83 ± 16.29
Week 431.38 ± 19.0014.29 ± 12.98
Week 2428.49 ± 20.868.46 ± 8.63
Week 4826.59 ± 18.6210.82 ± 15.53
SecondaryErythrocyte Sedimentation Rate (ESR), Median, From Baseline to Week 48

Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Median · mm/hr
Erythrocyte Sedimentation Rate (ESR), Median, From Baseline to Week 48
mm/hrDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline33.0 (23.00 to 43.00)33.50 (26.00 to 42.00)
Week 430.00 (16.50 to 39.50)9.50 (4.00 to 23.00)
Week 2425.00 (12.00 to 36.00)5.00 (3.00 to 8.00)
Week 4822.50 (14.00 to 31.50)5.50 (3.00 to 12.00)
SecondarySerum Interleukin (IL)-6 Level, Mean, From Baseline to Week 48

Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Mean · pg/mL
Serum Interleukin (IL)-6 Level, Mean, From Baseline to Week 48
pg/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline11.83 ± 19.7413.88 ± 43.77
Week 413.41 ± 29.98143.97 ± 427.01
Week 814.21 ± 26.82111.44 ± 280.34
Week 1615.40 ± 24.2666.20 ± 70.50
Week 2411.81 ± 24.0562.74 ± 53.40
Week 369.32 ± 15.2362.15 ± 68.08
Week 489.25 ± 15.1453.98 ± 57.25
SecondarySerum Interleukin (IL)-6 Level, Median, From Baseline to Week 48

Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Median · pg/mL
Serum Interleukin (IL)-6 Level, Median, From Baseline to Week 48
pg/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline5.21 (0.0 to 15.0)4.65 (0.0 to 419.0)
Week 45.31 (0.0 to 246.0)56.50 (0.0 to 3260.0)
Week 85.15 (0.0 to 214.0)58.65 (0.0 to 2650.0)
Week 165.01 (0.0 to 117.0)48.25 (0.0 to 494.0)
Week 243.53 (0.0 to 151.0)47.90 (0.0 to 286.0)
Week 364.01 (0.0 to 107.0)46.30 (14.8 to 608.0)
Week 483.85 (0.0 to 80.5)43.45 (0.0 to 439.0)
SecondarySerum Interleukin (IL)-6 Level, Mean Change From Baseline to Week 48

Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Mean · pg/mL
Serum Interleukin (IL)-6 Level, Mean Change From Baseline to Week 48
pg/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Week 41.11 ± 28.78130.60 ± 395.93
Week 82.43 ± 31.0097.22 ± 237.43
Week 163.07 ± 31.7157.10 ± 62.62
Week 240.13 ± 30.6353.33 ± 46.81
Week 36-3.48 ± 23.2352.26 ± 55.81
Week 48-1.60 ± 21.5440.01 ± 29.89
SecondarySerum Interleukin (IL)-6 Level, Median Change From Baseline to Week 48

Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Median · pg/mL
Serum Interleukin (IL)-6 Level, Median Change From Baseline to Week 48
pg/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Week 4-0.12 (-150.0 to 202.7)52.41 (-27.4 to 2841.0)
Week 80.83 (-148.6 to 210.5)52.35 (-9.8 to 2231.0)
Week 160.34 (-148.5 to 114.5)42.35 (-6.0 to 494.0)
Week 240.00 (-148.5 to 144.9)41.21 (-8.0 to 284.0)
Week 360.00 (-148.2 to 63.3)41.20 (0.9 to 474.0)
Week 480.00 (-150.0 to 46.0)32.96 (-11.8 to 138)
SecondarySerum Soluble Interleukin (IL)-6 Receptor Level, Mean, From Baseline to Week 48

Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Mean · ng/mL
Serum Soluble Interleukin (IL)-6 Receptor Level, Mean, From Baseline to Week 48
ng/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline42.16 ± 32.4142.22 ± 14.56
Week 446.07 ± 73.52486.58 ± 122.94
Week 845.71 ± 57.95546.59 ± 142.58
Week 1647.81 ± 68.22583.87 ± 164.36
Week 2441.35 ± 15.17587.28 ± 153.90
Week 3638.13 ± 11.22589.59 ± 140.63
Week 4849.27 ± 76.97571.48 ± 167.85
SecondarySerum Soluble Interleukin (IL)-6 Receptor Level, Median, From Baseline to Week 48

Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Median · ng/mL
Serum Soluble Interleukin (IL)-6 Receptor Level, Median, From Baseline to Week 48
ng/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline37.10 (17.0 to 340.0)39.00 (20.1 to 97.2)
Week 438.10 (19.4 to 775.0)482.50 (42.0 to 773.0)
Week 837.20 (17.6 to 612.0)536.00 (30.5 to 873.0)
Week 1638.95 (20.6 to 711.0)589.50 (27.4 to 1290.0)
Week 2439.30 (19.5 to 99.8)590.00 (23.2 to 945.0)
Week 3636.20 (21.1 to 67.5)591.00 (45.4 to 970.0)
Week 4836.00 (19.2 to 596.0)576.50 (23.4 to 973.0)
SecondarySerum Soluble Interleukin (IL)-6 Receptor Level, Mean Change From Baseline to Week 48

Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Mean · ng/mL
Serum Soluble Interleukin (IL)-6 Receptor Level, Mean Change From Baseline to Week 48
ng/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Week 43.96 ± 79.00444.23 ± 120.90
Week 83.31 ± 65.47501.09 ± 140.42
Week 166.04 ± 77.69539.21 ± 165.63
Week 24-1.29 ± 35.46540.98 ± 152.70
Week 36-4.31 ± 35.92544.89 ± 142.95
Week 487.23 ± 86.81525.66 ± 165.53
SecondarySerum Soluble Interleukin (IL)-6 Receptor Level, Median Change From Baseline to Week 48

Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline to Week 48
Reported as:
Median · ng/mL
Serum Soluble Interleukin (IL)-6 Receptor Level, Median Change From Baseline to Week 48
ng/mLDouble-Blind PlaceboDouble-Blind Tocilizumab
Week 40.20 (-318.4 to 709.5)437.80 (-13.4 to 724.3)
Week 80.20 (-305.9 to 560.8)489.90 (-14.1 to 823.0)
Week 160.25 (-316.4 to 679.0)542.30 (-28.0 to 1248.7)
Week 241.20 (-316.6 to 51.6)547.50 (-32.2 to 909.9)
Week 36-0.40 (-315.7 to 24.1)541.70 (-26.6 to 942.9)
Week 48-0.70 (-317.9 to 560.2)532.20 (-0.4 to 945.9)
SecondarySerum C-Reactive Protein (CRP) Level, Mean, From Baseline to Week 48

Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline up to Week 48
Reported as:
Mean · mg/L
Serum C-Reactive Protein (CRP) Level, Mean, From Baseline to Week 48
mg/LDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline7.43 ± 12.619.00 ± 14.76
Week 49.81 ± 20.790.85 ± 2.52
Week 249.89 ± 13.990.56 ± 1.19
Week 487.52 ± 12.801.58 ± 6.22
SecondarySerum C-Reactive Protein (CRP) Level, Median, From Baseline to Week 48

Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline up to Week 48
Reported as:
Median · mg/L
Serum C-Reactive Protein (CRP) Level, Median, From Baseline to Week 48
mg/LDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline3.82 (1.19 to 8.69)4.05 (1.30 to 9.48)
Week 43.71 (1.27 to 8.83)0.20 (0.20 to 0.50)
Week 244.15 (1.43 to 13.10)0.20 (0.20 to 0.47)
Week 483.67 (1.26 to 7.78)0.20 (0.20 to 0.59)
SecondarySerum Tocilizumab Concentration, Mean, From Baseline to Week 48

Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter

Time frame:
From Baseline to Week 48
Reported as:
Mean · ug/mL
Serum Tocilizumab Concentration, Mean, From Baseline to Week 48
ug/mLDouble-Blind Tocilizumab
Baseline0.00 ± 0.03
Week 430.92 ± 15.24
Week 841.82 ± 17.66
Week 1650.98 ± 23.33
Week 2454.34 ± 26.24
Week 3653.55 ± 29.25
Week 4854.67 ± 29.79
SecondarySerum Tocilizumab Concentration, Median, From Baseline to Week 48

Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter

Time frame:
From Baseline to Week 48
Reported as:
Median · ug/mL
Serum Tocilizumab Concentration, Median, From Baseline to Week 48
ug/mLDouble-Blind Tocilizumab
Baseline0.00 (0.0 to 0.2)
Week 428.70 (0.4 to 86.8)
Week 839.25 (8.3 to 97.6)
Week 1647.40 (9.5 to 120.0)
Week 2452.60 (7.6 to 117.0)
Week 3652.50 (4.0 to 138.0)
Week 4852.10 (0.4 to 145.0)
SecondaryCorrelation Between Low Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Mean · Units on a scale
Correlation Between Low Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline20.4 ± 6.9520.3 ± 5.56
Week 818.6 ± 7.7817.9 ± 5.84
Week 1617.9 ± 8.7116.2 ± 5.58
Week 2416.9 ± 9.3814.7 ± 5.61
Week 3616.2 ± 10.2413.2 ± 4.97
Week 4814.8 ± 9.8912.2 ± 6.03
SecondaryCorrelation Between Low Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Median · Units on a scale
Correlation Between Low Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline19.0 (10 to 40)20.0 (11 to 31)
Week 818.0 (4 to 43)16.0 (9 to 34)
Week 1617.0 (0 to 38)15.0 (8 to 30)
Week 2416.0 (0 to 42)14.0 (6 to 29)
Week 3614.0 (0 to 47)13.5 (5 to 27)
Week 4814.0 (0 to 43)12.5 (2 to 30)
SecondaryCorrelation Between Medium Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Mean · Units on a scale
Correlation Between Medium Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline20.4 ± 6.9519.1 ± 6.24
Week 818.6 ± 7.7817.2 ± 6.17
Week 1617.9 ± 8.7116.2 ± 6.10
Week 2416.9 ± 9.3814.6 ± 6.66
Week 3616.2 ± 10.2413.4 ± 6.20
Week 4814.8 ± 9.8911.6 ± 5.72
SecondaryCorrelation Between Medium Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Median · Units on a scale
Correlation Between Medium Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline19.0 (10 to 40)18.0 (10 to 35)
Week 818.0 (4 to 43)17.0 (5 to 31)
Week 1617.0 (0 to 38)16.0 (5 to 27)
Week 2416.0 (0 to 42)14.0 (3 to 28)
Week 3614.0 (0 to 47)13.0 (2 to 25)
Week 4814.0 (0 to 43)11.0 (0 to 24)
SecondaryCorrelation Between High Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Mean · Units on a scale
Correlation Between High Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline20.4 ± 6.9519.8 ± 6.82
Week 818.6 ± 7.7817.9 ± 7.35
Week 1617.9 ± 8.7116.7 ± 7.31
Week 2416.9 ± 9.3815.6 ± 7.50
Week 3616.2 ± 10.2413.7 ± 7.07
Week 4814.8 ± 9.8912.8 ± 7.20
SecondaryCorrelation Between High Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Median · Units on a scale
Correlation Between High Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Baseline19.0 (10 to 40)19.0 (11 to 33)
Week 818.0 (4 to 43)17.5 (5 to 32)
Week 1617.0 (0 to 38)15.0 (6 to 33)
Week 2416.0 (0 to 42)15.0 (2 to 31)
Week 3614.0 (0 to 47)11.0 (4 to 30)
Week 4814.0 (0 to 43)11.0 (4 to 34)
SecondaryChange in Mean Modified Rodnan Skin Score (mRSS) at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Mean · Units on a scale
Change in Mean Modified Rodnan Skin Score (mRSS) at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Low Exposure-5.3 ± 7.77-8.0 ± 5.85
Medium Exposure-5.3 ± 7.77-7.5 ± 5.06
High Exposure-5.3 ± 7.77-7.0 ± 6.26
SecondaryChange in Median Modified Rodnan Skin Score (mRSS), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Median · Units on a scale
Change in Median Modified Rodnan Skin Score (mRSS), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
Units on a scaleDouble-Blind PlaceboDouble-Blind Tocilizumab
Low Exposure-5.5 (-25 to 22)-8.0 (-19 to 4)
Medium Exposure-5.5 (-25 to 22)-7.0 (-18 to 2)
High Exposure-5.5 (-25 to 22)-6.0 (-20 to 6)
SecondaryChange in Mean Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Mean · Percent
Change in Mean Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
PercentDouble-Blind PlaceboDouble-Blind Tocilizumab
Low Exposure-4.264 ± 8.1550.144 ± 6.474
Medium Exposure-4.264 ± 8.155-0.161 ± 6.440
High Exposure-4.264 ± 8.155-0.297 ± 7.895
SecondaryChange in Median Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48

In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.

Time frame:
From Baseline to Week 48
Reported as:
Median · Percent
Change in Median Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
PercentDouble-Blind PlaceboDouble-Blind Tocilizumab
Low Exposure-3.910 (-31.47 to 13.47)0.525 (-14.25 to 11.38)
Medium Exposure-3.910 (-31.47 to 13.47)-1.600 (-13.83 to 17.00)
High Exposure-3.910 (-31.47 to 13.47)0.000 (-10.55 to 19.69)
SecondarySummary of Adverse Events Up to Week 96

Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 21.1. NMSC = Non-Melanoma Skin Cancer

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Summary of Adverse Events Up to Week 96
Percentage of participantsDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
At least one Adverse Event (AE)77.485.677.571.7
Withdrawn from study due to an AE12.36.71.11.1
Fatal AE2.81.01.11.1
Serious Adverse Events (SAEs)17.012.57.910.9
SAE leading to withdrawal from treatment5.74.81.11.1
SAE leading to dose modification/interruption5.72.94.53.3
SAE related to study drug6.61.03.43.3
AE leading to withdrawal from treatment12.36.71.11.1
AE leading to dose modification/interruption26.419.228.122.8
AE related to study drug34.046.233.734.8
Related AE leading to withdrawal from treatment1.91.01.11.1
Related AE with dose modification/interruption17.011.512.414.1
Serious Infections and Infestations AEs6.61.93.41.1
Infections and Infestations AEs50.052.946.139.1
Opportunistic Infections AEs0.91.001.1
Malignancy AEs0.91.901.1
Malignancy AEs (excluding NMSC)0.91.901.1
Serious Hepatic AEs0000
Serious Stroke AEs0000
Serious Myocardial Infarction AEs1.9000
Anaphylactic Reaction AEs0000
Anaphylactic Reaction AEs (Sampson's Criteria)0000
Serious Gastrointestinal Perforation AEs0000
Serious Bleeding AEs0.9000
Serious Demyelinating AEs0000
SecondaryIncidence and Severity of Adverse Events Up to Week 96

Adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) severity grade: 1 = mild, 2 = moderate, 3 = severe and/or requiring medical intervention but not life-threatening, 4 = life-threatening consequences, and 5 = death.

Time frame:
Up to Week 96
Reported as:
Number · Number of participants
Incidence and Severity of Adverse Events Up to Week 96
Number of participantsDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
Grade 161786053
Grade 263534135
Grade 3211898
Grade 47045
Grade 53111
SecondaryNumber of Participants With Adverse Events Leading to Death Up to Week 96
Time frame:
Up to Week 96
Reported as:
Number · Number of participants
Number of Participants With Adverse Events Leading to Death Up to Week 96
Number of participantsDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
CARDIAC FAILURE CHRONIC1000
MYOCARDITIS1000
MYOCARDIAL INFARCTION1000
DEATH0100
BRAIN INJURY0010
PULMONARY HYPERTENSION0001
SecondaryPercentage of Participants With Change in Digital Ulcer Count at Week 96

A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.

Time frame:
From Baseline to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Change in Digital Ulcer Count at Week 96
Percentage of participantsDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
No change0091.183.3
Increase by 10004.8
Increase by 20001.2
Increase by 30001.2
Increase by 40000
Increase by >40001.2
Decrease by 1003.84.8
Decrease by 2002.50
Decrease by 3001.31.2
Decrease by 4001.31.2
Decrease by >40000
Baseline missing0001.2
SecondaryPercentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline From Week 48 to 96

Reported were the percentage of participants with post-baseline treatment-induced anti-TCZ antibodies. Positive samples underwent additional analyses: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.

Time frame:
Open-label period from Week 48 to 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline From Week 48 to 96
Percentage of ParticipantsTocilizumab, Then Tocilizumab Open Label
Treatment-Induced Anti-TCZ Antibodies0.0
Anti-TCZ Antibodies of Neutralizing Potential0.0
Anti-TCZ Antibodies of IgE0.0
SecondaryErythrocyte Sedimentation Rate (ESR) Up to Week 96

Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
Up to Week 96
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate (ESR) Up to Week 96
mm/hrDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
Baseline34.72 ± 18.4934.83 ± 16.29——
Week 431.38 ± 19.0014.29 ± 12.98——
Week 2428.49 ± 20.868.46 ± 8.63——
Week 4826.23 ± 18.5310.89 ± 15.39——
Week 72——9.54 ± 9.478.29 ± 10.13
Week 96——9.67 ± 8.678.06 ± 8.86
SecondarySerum Interleukin (IL)-6 Level, Mean, From Baseline to Week 96

Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
Up to Week 96
Reported as:
Mean · pg/mL
Serum Interleukin (IL)-6 Level, Mean, From Baseline to Week 96
pg/mLDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
Baseline11.85 ± 19.7313.86 ± 43.78——
Week 413.41 ± 29.98144.75 ± 429.14——
Week 814.21 ± 26.82111.44 ± 280.34——
Week 1615.40 ± 24.2666.20 ± 70.50——
Week 2411.81 ± 24.0562.74 ± 53.40——
Week 369.32 ± 15.2362.15 ± 68.08——
Week 489.10 ± 14.8853.34 ± 56.80——
Week 96——62.60 ± 57.2152.03 ± 46.51
SecondarySerum Soluble Interleukin (IL)-6 Receptor Level, Mean, Up to Week 96

Serum Soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
Up to Week 96
Reported as:
Mean · ng/mL
Serum Soluble Interleukin (IL)-6 Receptor Level, Mean, Up to Week 96
ng/mLDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
Baseline42.23 ± 32.5642.15 ± 14.50——
Week 446.07 ± 73.52487.70 ± 123.02——
Week 845.71 ± 57.95546.59 ± 142.58——
Week 1647.81 ± 68.22583.87 ± 164.36——
Week 2441.35 ± 15.17587.28 ± 153.90——
Week 3638.13 ± 11.22589.59 ± 140.63——
Week 4849.51 ± 76.17566.49 ± 175.25——
Week 96——558.38 ± 256.86565.31 ± 159.82
SecondarySerum C-Reactive Protein (CRP) Level, Mean, Up to Week 96

Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.

Time frame:
From Baseline up to Week 96
Reported as:
Mean · mg/L
Serum C-Reactive Protein (CRP) Level, Mean, Up to Week 96
mg/LDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
Baseline7.42 ± 12.628.99 ± 14.76——
Week 410.05 ± 20.820.85 ± 2.50——
Week 249.89 ± 13.990.56 ± 1.19——
Week 487.40 ± 12.621.75 ± 6.43——
Week 72——0.57 ± 0.800.92 ± 3.61
Week 96——0.90 ± 2.730.97 ± 5.08
SecondarySerum Tocilizumab Concentration, Mean, Up to Week 96

Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter

Time frame:
Up to Week 96
Reported as:
Mean · ug/mL
Serum Tocilizumab Concentration, Mean, Up to Week 96
ug/mLDouble-Blind Tocilizumab, Then Open Label Tocilizumab
Baseline0.00 ± 0.03
Week 430.76 ± 15.23
Week 841.82 ± 17.66
Week 1650.98 ± 23.33
Week 2454.34 ± 26.24
Week 3653.55 ± 29.25
Week 4854.87 ± 29.69
Week 9649.99 ± 26.19

Adverse events

Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Placebo3/106 (2.8%)18/106 (17%)59/106 (55.7%)
Double-Blind Tocilizumab1/104 (1%)13/104 (12.5%)60/104 (57.7%)
Placebo, Then Tocilizumab Open Label1/89 (1.1%)7/89 (7.9%)46/89 (51.7%)
Tocilizumab, Then Tocilizumab Open Label1/92 (1.1%)10/92 (10.9%)28/92 (30.4%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
PNEUMONIAInfections and infestations3/1060/1041/891/92
ARRHYTHMIACardiac disorders0/1060/1041/890/92
CARDIAC TAMPONADECardiac disorders0/1060/1041/890/92
CARDIO-RESPIRATORY ARRESTCardiac disorders0/1060/1041/890/92
RECTAL PROLAPSEGastrointestinal disorders0/1060/1041/890/92
INFECTIVE TENOSYNOVITISInfections and infestations0/1060/1041/890/92
SEPSISInfections and infestations1/1060/1041/890/92
FEMORAL NECK FRACTUREInjury, poisoning and procedural complications0/1060/1041/890/92
TENDONITISMusculoskeletal and connective tissue disorders0/1060/1041/890/92
BRAIN INJURYNervous system disorders0/1060/1041/890/92
Most frequent other events
Showing 10 of 16
Most frequent other events
EventDouble-Blind PlaceboDouble-Blind TocilizumabPlacebo, Then Tocilizumab Open LabelTocilizumab, Then Tocilizumab Open Label
SKIN ULCERSkin and subcutaneous tissue disorders12/10615/10416/8911/92
ARTHRALGIAMusculoskeletal and connective tissue disorders14/10612/1043/895/92
NASOPHARYNGITISInfections and infestations8/10613/1049/894/92
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations11/10612/10410/894/92
URINARY TRACT INFECTIONInfections and infestations10/1065/1047/891/92
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders6/1064/1048/892/92
FATIGUEGeneral disorders7/1068/1040/890/92
INTERSTITIAL LUNG DISEASERespiratory, thoracic and mediastinal disorders8/1062/1041/891/92
DIARRHOEAGastrointestinal disorders7/1066/1046/895/92
GASTROENTERITISInfections and infestations2/1067/1040/893/92

Baseline characteristics

The analysis was conducted on the safety population, i.e. all randomized patients who received at least one dose of study drug and provided data from at least one post dose safety assessment.

Age, Continuous
Age, Continuous(Years)Double-Blind Placebo, Then Tocilizumab Open LabelDouble-Blind Tocilizumab, Then Tocilizumab Open LabelTotal
Mean49.3 ± 12.647.0 ± 12.248.2 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Placebo, Then Tocilizumab Open LabelDouble-Blind Tocilizumab, Then Tocilizumab Open LabelTotal
Female9081171
Male162339
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Placebo, Then Tocilizumab Open LabelDouble-Blind Tocilizumab, Then Tocilizumab Open LabelTotal
Hispanic or Latino261339
Not Hispanic or Latino7989168
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind Placebo, Then Tocilizumab Open LabelDouble-Blind Tocilizumab, Then Tocilizumab Open LabelTotal
American Indian or Alaska Native314
Asian91625
Native Hawaiian or Other Pacific Islander000
Black or African American325
White9085175
More than one race000
Unknown or Not Reported101
08

Study locations

83 sites
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • St. Joseph's Heritage Healthcare
    Fullerton, California 92835, United States
  • Univ of Calif., Los Angeles; Rheumatology
    Los Angeles, California 90025, United States
  • Arthritis Associates of Southern California
    Los Angeles, California 90045, United States
  • Georgetown Uni. Hosp.; Rheumatology, Immunology and Allergy Dept.
    Washington, District of Columbia 20007, United States
  • Rheumatology Assoc. of S. Florida - Clinical Research Center
    Boca Raton, Florida 33486, United States
  • Millenium Research
    Ormond Beach, Florida 32174, United States
  • Boston Univ Med Center - AC
    Boston, Massachusetts 02118, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-0934, United States
  • West Michigan Rheumatology, PLLC
    Grand Rapids, Michigan 49546, United States
  • Joint & Muscle Research Institute
    Charlotte, North Carolina 28204, United States
  • Arthritis and Rheumatology; Center of Oklahoma PLLC
    Oklahoma City, Oklahoma 73103, United States
  • Thomas Jefferson Uni ; Division of Rheumatology
    Philadelphia, Pennsylvania 19131, United States
  • Clinical Research Center of Reading
    Wyomissing, Pennsylvania 19610, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Metroplex Clinical Research
    Dallas, Texas 75231, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Hospital Britanico; Haematology
    Buenos Aires, C1280AEB, Argentina
  • Sanatorio Parque S.A.
    Rosario, Santa FE, S2000DSV, Argentina
  • Centro de Investigaciones Reumatologicas Tucuman
    Tucuman, 4000, Argentina
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • MHAT Kaspela; Rheumatology
    Plovdiv, 4002, Bulgaria
  • MHAT-Plovdiv AD; Reumatology Department
    Plovdiv, 4003, Bulgaria
  • MHAT St.Ivan Rilski; Rheumtology Department
    Sofia, 1612, Bulgaria
  • MHAT Sv.Ivan Rilski; Clinic of Rheumatology
    Sofia, 1612, Bulgaria
  • St. Paul's Hospital University of British Colambia Division of Hematology
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Mount Sinai Hospital; Rebecca Macdonald Centre For Arthritis & Autoimmune Disease
    Toronto, Ontario M5G 1X5, Canada
  • Aarhus Universitetshospital Skejby, Hud- og Kønssygdomme
    Aarhus N, 8200, Denmark
  • Bispebjerg Hospital, Dermatologisk afdeling
    København NV, 2400, Denmark
  • Hopital Claude Huriez; Internal Medicine
    Lille, 59037, France
  • Asklepios Kllinikum Bad Abbach; Klinik für Rheumatologie und Klinische Immunologie
    Bad Abbach, 93077, Germany
  • Kerckhoff-Klinik; Rheumatologie&klin.Immunologie
    Bad Nauheim, 61231, Germany
  • Universitätsklinikum Dresden; Technische Universität Dresden; Rheumatologie, Innere Medizin III
    Dresden, 01307, Germany
  • Klinikum der Universitat Munchen; Bereich Pettenkoferstr; Rheumaeinheit der medizinischen Klinik IV
    München, 80336, Germany
  • Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II
    Tübingen, 72076, Germany
  • Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens
    Athens, 115 27, Greece
  • University Hospital of Patras; Rheumatology
    Patras, 265 04, Greece
  • National Institute of Rheumatology and Physiology
    Budapest, 1023, Hungary
  • Pécsi Tudományegyetem Klinikai Központ: Immunológiai és Reumatológiai Klinika
    Pécs, 7632, Hungary
  • Policlinico Universitario-II Università di Napoli; Reumatologia
    Napoli, Campania 80131, Italy
  • Uni ' Cattolica Del Sacro Cuore; Facoltà Di Medicina E Chirurgia A.Gemelli-Clinica Reumatologica
    Roma, Lazio 00168, Italy
  • Ospedale Maggiore Policlinico; Unità Operativa Complessa di Allergologia e Immunologia Clinica
    Milano, Lombardia 20122, Italy
  • Ospedale Careggi Villa Monnatessa ; Sezione Di Reumatologia
    Firenze, Toscana 50139, Italy
  • Gunma University Hospital
    Gunma, 371-8511, Japan
  • Sapporo Medical University Hospital
    Hokkaido, 060-8543, Japan
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • Kanazawa University Hospital
    Ishikawa, 920-8641, Japan
  • St. Marianna University School of Medicine Hospital
    Kanagawa, 216-8511, Japan
  • Hospital of the University of Occupational and Environmental Health,Japan
    Kitakyushu-shi, 807-8556, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Tohoku University Hospital
    Miyagi, 980-8574, Japan
  • Osaka University Hospital
    Osaka, 565-0871, Japan
  • Nippon Medical School Hospital
    Tokyo, 113-8603, Japan
  • The University of Tokyo Hospital
    Tokyo, 113-8655, Japan
  • Klaipeda University Hospital; Department of Rheumatology
    Klaipeda, LT - 92288, Lithuania
  • Vilnius University Hospital Santariskiu Clinic Public Insti
    Vilnius, 08661, Lithuania
  • Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán
    Mexico City, Tlalpan 14000, Mexico
  • Unidad De Enfermedades; Cronico Degenerativas, SC.
    Mexico, 44620, Mexico
  • Cliditer SA de CV
    Miexico City, 06700, Mexico
  • Academisch Ziekenhuis Leiden; Dept of Rheumatology
    Leiden, 2333 ZA, Netherlands
  • Szpital Uniwersytecki; nr 2 im. Dr J. Biziela; Klinika Reumatologii i Ukladowych Chorob
    Bydgoszcz, 85-168, Poland
  • Uniwersyteckie Centrum Kliniczne; Klinika Chorob Wewnetrznych, Chorob Tkanki Łacznej i Geriatrii
    Gdansk, 80-952, Poland
  • Gornoslaskie Centrum Medyczne
    Katowice, 40-635, Poland
  • Szpital Specjalistyczny im Jozefa Dietla; Centrum Reumatologii, Immunologii i Rehabilitacji, I Oddzi
    Krakow, 31-121, Poland
  • SPSK NR 4; Reumatologii i Ukladowych Chorob Tkanki
    Lublin, 20-954, Poland
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. Prof. Eleonory Reicher
    Warszawa, 02-637, Poland
  • Hospital Garcia de Orta; Servico de Reumatologia
    Almada, 2801-951, Portugal
  • Hospital Prof. Dr. Fernando Fonseca; Medicina IV
    Amadora, 3814-501, Portugal
  • Puerto Rico Clinical & Translational Research Consortium
    San Juan, 00936-5067, Puerto Rico
  • Cantacuzino Hospital; Department of Internal Medicine and Rheumatology
    Bucharest, 020475, Romania
  • Spitalul Judetean Cluj; Sectia de Reumatologie
    Cluj-napoca, 400006, Romania
  • Hospital de la Santa Creu i Sant Pau; Servicio de Medicina Interna/Reumatologia
    Barcelona, 08025, Spain
  • Hospital Universitario Vall d'Hebron; Servicio de Medicina Interna
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Reumatología
    Madrid, 28007, Spain
  • Universitätsspital Basel; Rheumatologische Poliklinik
    Basel, 4031, Switzerland
  • Universitätsspital Zürich; Klinik für Rheumatologie
    Zürich, 8091, Switzerland
  • Queen Elizabeth Hospital; Rheumatology Dept.
    Birmingham, B15 2TH, United Kingdom
  • Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
  • Chapel Allerton Hospital; Leeds Institution of Rheumatology Medicine
    Leeds, LS7 4SA, United Kingdom
  • Uni Hospital Aintree; Academic Rheumatology Unit
    Liverpool, L9 7AL, United Kingdom
  • Royal Free Hospital; Department of Rheumatology
    London, NW3 2QG, United Kingdom
  • Freeman Hospital; Musculoskeletal Unit
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022 Mar 15;205(6):674-684. doi: 10.1164/rccm.202103-0714OC. PubMed 34851799 ↗
  • Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D; focuSSced Investigators. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021 Jul;73(7):1301-1310. doi: 10.1002/art.41668. Epub 2021 May 25. PubMed 33538094 ↗
  • Gao X, Jia G, Guttman A, DePianto DJ, Morshead KB, Sun KH, Ramamoorthi N, Vander Heiden JA, Modrusan Z, Wolters PJ, Jahreis A, Arron JR, Khanna D, Ramalingam TR. Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. Cell Rep Med. 2020 Nov 17;1(8):100140. doi: 10.1016/j.xcrm.2020.100140. eCollection 2020 Nov 17. PubMed 33294861 ↗
  • Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28. Erratum In: Lancet Respir Med. 2020 Oct;8(10):e75. doi: 10.1016/S2213-2600(20)30423-9. Lancet Respir Med. 2021 Mar;9(3):e29. doi: 10.1016/S2213-2600(21)00107-7. PubMed 32866440 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jan 2018, 25 months.

Results were first posted in Apr 2019, 1 year 2 months after primary completion.

Of 17 phase 3 interventional studies under Scleroderma, Systemic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2015
First posted
May 25, 2015
StartActual
Nov 20, 2015
Primary completionActual
Jan 15, 2018
CompletionActual
Feb 4, 2019
Results first posted
Apr 3, 2019
Last update
Mar 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02453256
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 25, 2015
Start date
Nov 20, 2015
Primary completion
Jan 15, 2018
Completion
Feb 4, 2019
Results posted
Apr 3, 2019
Last update
Mar 9, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion